Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Samsung Bioepis Study shows Structural Similarity Between Aflibercept Biosimilar and Eylea®

Jun 15, 2024

On 15 June2024, Ophthalmology and Therapy published the results of a Samsung Bioepis-sponsored study which assessed the analytical similarity between Samsung Bioepis’ aflibercept biosimilar, SB15, and Regeneron’s Eylea® (aflibercept) sourced from the US and EU.  The results showed that SB15 was analytically “highly similar” to US/EU sourced Eylea®, with comparable primary and higher-order structure, no meaningful differences in physiochemical properties in terms of size and charge heterogeneity, and similarity in biological activities.

Samsung Bioepis’ SB15 was approved in the US in May 2024 (as Opuviz® (aflibercept-yszy)) and in Korea in February 2024 as Aflilvu®.